- Case Report
- Open Access
Novel microduplication of CHL1 gene in a patient with autism spectrum disorder: a case report and a brief literature review
© The Author(s). 2016
Received: 23 March 2016
Accepted: 23 June 2016
Published: 27 June 2016
The cell adhesion molecule L1-like (CHL1 or CALL) gene is located on chromosome 3p26.3, and it is highly expressed in the central and peripheral nervous systems. The protein encoded by this gene is a member of the L1 family of neural cell adhesion molecules, and it plays a role in nervous system development and synaptic plasticity. Moreover, studies of mice have revealed that CHL1 is a prime candidate gene for a dosage-sensitive autosomal form of mental retardation. To date, four patients with a microdeletion and two with a microduplication of 3p26.3 encompassing only the CHL1 gene have been reported in literature.
In the present study, we have described a 16-month-old boy with autism spectrum disorder (ASD), developmental delay and minor dysmorphic facial features. This is the first report of a duplication of 3p26.3 including only the CHL1 gene in an ASD patient, and this duplication is the smallest reported to date in this gene. We also reviewed CHL1 gene mutation cases and examined whether this gene has an important role in cognitive function.
We conclude that both CHL1 deletions and duplications are likely responsible for the patient’s impaired cognitive function, and CHL1 may be an intriguing ASD candidate gene.
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by impairments in social interaction and verbal and non-verbal communication, as well as restricted and repetitive behaviors. In the United States, the most recent estimate as of 2010 is that 1 in every 68 children have some form of ASD . Genetic factors play a prominent role in ASD pathogenesis. According to recent studies, the majority of copy number variations (CNVs) affect only one copy of a gene (which can be either deleted or duplicated), suggesting that abnormal gene dosage or expression might play a key role in susceptibility to ASD [2, 3].
The cell adhesion molecule L1-like (CHL1 or CALL) gene is located on chromosome 3p26.3, and it is highly expressed in the central and peripheral nervous systems. The protein encoded by this gene is a member of the L1 family of neural cell adhesion molecules, and it plays a role in nervous system development and synaptic plasticity [4, 5]. To date, four patients with a microdeletion of 3p26.3 including only the CHL1 gene have been reported in the literature. All of these patients presented with cognitive impairment characterized by learning and language difficulties [6–8]. Frints et al. have studied CHL1 expression in the hippocampi of CHL1 +/− mice and have found that it is half of that observed in wild-type littermates, indicating the existence of a gene dosage effect. This group has suggested that a 50 % reduction in CHL1 expression in the developing brain results in cognitive deficits . However, less is known about the reciprocal microduplication of this gene.
To the best of our knowledge, only two families with a microduplication of 3p26.3 including only the CHL1 gene have been described to date, including one intellectually disabled girl with epilepsy and one male patient with developmental delay (DD), symptoms of hyperactivity, a short attention span and speech delay. The duplications detected by array comparative genomic hybridization (CGH) were 1.07 and 0.85 Mb in size, respectively . Here, we describe a male patient with ASD and DD for whom array CGH analysis revealed the presence of a 0.69 Mb duplication of 3p26.3. The duplication was transmitted from his normal mother and included only the CHL1 gene.
Tassano et al. have reviewed CHL1 gene deletion cases. In contrast, here, we review the phenotypic and molecular features of CHL1 gene duplication cases and assess whether this gene plays an important role in cognitive function.
Cognitive/developmental evaluation using the Bayley Scales of Infant Development-2 showed that his cognitive and language skills, as well as his motor skills, were well behind for his age (MDI < 50; and PDI = 66). The Autism Diagnostic Observation Schedule (ADOS)-Toddler Module was used for autism screening. The results of this test revealed that the patient had a social affect score of 20, a restricted and repetitive behavior score of 5 and an overall total score of 25, indicating a likely diagnosis of moderate-to-severe ASD. His was finally diagnosed with ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria.
His mother was a 37-year-old female who had considered herself healthy throughout her life. Her childhood had been unremarkable, and she did not show any DD, not even when she was young. She scored in the normal range on the Broad Autism Phenotype Questionnaire (BAPQ)  and Symptom Checklist-90 (SCL-90) .
In the present study, we describe a 16-month-old boy with ASD, DD and minor dysmorphic facial features. This is the first report of a duplication of 3p26.3 including only the CHL1 gene in an ASD patient, and the duplication described here is the smallest reported to date involving this gene.
The CHL1 gene encodes a neural cell adhesion protein that belongs to the immunoglobulin superfamily. It is located on chromosome 3p26.3 and is highly expressed in the central and peripheral nervous systems. It plays a role in regulating neuronal migration and neurite overgrowth in the developing brain. Furthermore, CHL1 was expressed in the dorsal thalamus and on fibers along the thalamocortical projection in the ventral telencephalon and cortex. It could also play a vital role in thalamocortical connectivity . In a study of CHL1-deficient (CHL1 −/−) mice, researchers found that GABAergic synaptic connectivity due to the gene mutation resulted in enhanced synaptic elimination, leading to microgliosis, increased expression of interleukin-6 and the loss of parvalbumin-expressing interneurons and ultimately impaired synaptic plasticity . Moreover, studies of mice have found that CHL1 is a dosage-sensitive gene [4, 5, 12]. In humans, mutation of the CHL1 gene has been associated with distal 3p deletion syndrome (OMIM 613792). This syndrome is a rare contiguous genetic disorder involving deletion of chromosome 3p25-p26 and is characterized by DDs, low birth weight, growth retardation, micro- and brachycephaly, ptosis, a long philtrum, micrognathia, and low-set ears [13, 14]. The CHL1 gene is the most telomeric gene known on 3p, and it has been suggested to be candidate gene for cognitive impairment in 3p syndrome patients [4, 15].
To date, four familial cases presenting with a heterozygous deletion of chromosome 3p26.3 including only the CHL1 gene have been reported. First, a 6-year-old boy was reported who presented with microcephaly, short stature, mild mental retardation, learning and language delays, and strabismus. His gene deletion was transmitted from his normal mother . Next, two affected siblings whose deletions were transmitted from their normal father were reported who presented with microcephaly, mild mental retardation, and learning and language difficulties . Finally a 12-year-old boy was reported who presented with slow physical development, microcephaly, temper tantrums, and severe learning disabilities . All subjects exhibited verbal DD during the first 2 years of life and required specific therapy. The chromosomal deletions of 3p26.3 present in all four of these patients ranged from 500 Kb to 1.0 Mb in size and included only the CHL1 gene. The deletions were inherited from an apparently unaffected parent in three cases (data not available in one case) .
Comparison of clinical and molecular findings associated with 3p26.3 duplication, including only the CHL1 gene, between the present study and previous studies
Shoukier et al. 
Palumbo et al. 
1 years and 4 months
2 years and 3 months
Maternal grandmother with schizophrenia
No family history
No family history
9.95 kg (10–20th percentile)
57 kg (50th percentile)
15 kg (75–90th percentile)
80.1 cm (20–50th percentile)
157 cm (25th percentile)
96 cm (90–97th percentile)
Dysmorphic facial features
Mild hypertelorism, short mandible and protuberant forehead
No dysmorphic facial features
Minor dysmorphic facial features, including mild hypertelorism, down-slanting, long palpebral fissures with eversion of lateral third of lower eyelids, long philtrum, thin upper lip, and mildly prominent ear lobes
Age at walking
Multifocal sharp waves and sharp and slow-wave complexes
Fragile X screening
Most of the genetic aberrations in these seven patients were transmitted from a normal parent (three were maternal, two were paternal, one was de novo and no data were available in one case). These observations are suggestive of incomplete penetrance. In addition, Chl1+/− mice have been demonstrated to have a phenotypic spectrum ranging from wild-type to knockout behaviors . Another possible explanation would be the two-hit model . Other undetected CNVs might exist within the Array CGH in our patient; these mutations together with the CHL1 duplication could have caused the abnormalities in the child but not affected his mother. In addition, apart from the microarray-analyses, microscopically visible CNVs (CG-CNVs) might be another possibility . Moreover, an apparently unaffected parent who carries the deletion could also have subtle associated phenotypic features that become evident upon further clinical evaluation. Other possibilities that may account for the phenotypic variability among these patients include differences in genetic background, epigenetic phenomena, expression or regulatory variation, and the unmasking of recessive variants located on the other allele [7, 18].
Because the CHL1 gene plays an important role in regulating neuronal migration and neurite overgrowth in the developing brain and all seven patients with a CHL1 gene mutation showed DD, we conclude that both CHL1 deletion and duplication are likely to result in impaired cognitive function in patients. One interpretation of the gene balance hypothesis is that under- and overexpression phenotypes are identical, or at least similar, because both deletions and duplications disrupt an identical multimeric regulatory protein complex (by disruption of the stoichiometry of protein subunits encoded by the associated genes) . The relationship between gene dosage and phenotype is complex. Conrad and Antonarakis have proposed three alternatives to explain this relationship that are each characteristic of certain categories of genes. Based on the reports in the literature, we hypothesize that the CHL1 gene corresponds with the third alternative, which involves certain functional gene classes enriched in transcriptional regulators and signaling molecules that cause phenotypic changes when both under- and overexpressed (haploinsufficiency and pathogenic gene duplication). Both deletions and duplications are known to occur within the same chromosomal region in other diseases, for example, the progressive neurodegenerative disorder Rett syndrome, which almost exclusively affects females in its classical form and is due to MECP2 haploinsufficiency. Severe mental retardation and neurological symptoms with features of Rett syndrome in males can also be caused by MECP2 duplication .
With regard to association of the CHL1 gene with ASD, Weehi et al. have identified a patient with a 3p26.3 microduplication encompassing part of the CHL1 gene as well as the CNTN6 gene who presented with motor and speech DDs and some autistic features. Features in this patient suggestive of ASD included repetitive activities, preoccupation with spinning wheels, resistance to changes in routine, and heightened sensitivity to people touching his legs. Overall, however, he was not considered to have ASD . Moghadasi et al. studied the clinical consequences of a terminal deletion of the short arm of chromosome 3 in four generations of a family. They detected a 2.9 Mb deletion in the short arm of chromosome 3 in 7/13 family members that contained the candidate genes CHL1 (OMIM 607416), CNTN4 (OMIM 607280), and CNTN6 (OMIM 607220). The sister of the index patient had autism, speech delay, and learning difficulties . In addition, 3p26.3 microduplication has been reported in a study of CNVs in extended ASD families, but this aberration did not affect any genes and was located 109 Kb upstream of CHL1 . In the present study, we report a terminal duplication of 3p26.3 confined to the CHL1 gene in a boy with ASD. ASD is a group of neurodevelopmental disorders. The etiology and pathogenesis are still unknown. However, some studies have shown that the pathogenesis of ASD during early development of the brain could be relevant to disruptions of serotonin signaling . CHL1 is a modulator of the serotonergic system; the signal transduction pathways are regulated by constitutive activation of the serotonin 2c (5-HT2c) receptor by CHL1 . Another study discussed the genome-wide expression profiling of human lymphoblastoid cell lines and found that CHL1 is a putative selective serotonin reuptake inhibitor (SSRI) response biomarker . Therefore, CHL1 may be an intriguing ASD candidate gene, and it is likely responsible for the cognitive function impairments of ASD patients with a CHL1 gene mutation.
In the present study, we have described a 16-month-old boy with ASD, DD and minor dysmorphic facial features. This is the first report of a duplication of 3p26.3 confined to the CHL1 gene in an ASD patient, and it is the smallest reported duplication to date. We have also reviewed CHL1 gene mutation cases from the literature and examined whether this gene plays an important role in cognitive function. Although some clinical symptoms differ among these patients, such as epilepsy and some autistic features, all of the subjects showed impaired cognitive function. Thus, both heterozygous deletions and duplications of the CHL1 gene may be considered in the etiology of a new emerging syndrome characterized by DD and other possible symptoms. Because the number of reports is limited, the identification of new cases and further functional studies are required to confirm the exact function of the CHL1 gene in cognitive development.
Array CGH was performed on DNA extracted from the peripheral blood of the patient using commercially available arrays (Agilent SurePrint G3 Human CGH Microarray 1 × 1 mol/l, Agilent Santa Clara, California, USA). The UCSC Genome Browser database (GRCh37/hg19, Feb. 2009) was used as reference of structural variations identified in healthy human samples.
Real-time quantitative polymerase chain reaction (qPCR) was performed (SuperReal PreMix Plus, TIANGEN, China) to verify the presence of the CHL1 microduplication in this patient and to determine whether it was inherited. Three pairs of primers were designed using IDT, an online primer-designing tool (https://www.idtdna.com/Primerquest), for exons 4, 12 and 26 of CHL1 gene transcript variant 1. Relative quantification was performed using a standard curve against control amplicons of the ALB and PMP22 genes according to the manufacturer’s instructions (LightCycler® 480 Instrument, Roche, Germany).
ADOS, autism diagnostic observation schedule; ASD, autism spectrum disorder; BAPQ, broad autism phenotype questionnaire; CGH, comparative genomic hybridization; CHL1, cell adhesion molecule L1-like; CNVs, copy number variations; DD, developmental delay; DMS-V, diagnostic and statistical manual of mental disorders, fifth edition; SCL-90, symptom checklist-90; qPCR, real-time quantitative polymerase chain reaction
We thank the patients’ parents for their kind participation and support.
This work was supported by the National Natural Science Foundation of China (81371270) and the “Youth Science Talents to Sail Plan” of the Science and Technology Commission, Shanghai (14YF1400700).
Availability of data and materials
CYL participated in the design of the study, performed the statistical analysis and drafted the manuscript. CXL conducted the molecular genetic studies. BZ and CH performed the clinical examinations. XX conceived of the study, participated in its design and coordination and helped to edit the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the parents for publication of this case report and the accompanying images.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Wingate M, Kirby RS, Pettygrove S. Prevalence of autism Spectrum disorder among children aged 8 years − autism and Developmental Disabilities Monitoring Network, 11 sites, United States; 2010. MMWR Surveill Summary. 2014;63:1–21.Google Scholar
- Bayou N, M’Rad R, Ahlem B, Béchir Helayem M, Chaabouni H. Autism: an overview of genetic aetiology. Tunis Med. 2008;86:573–8.PubMedGoogle Scholar
- Toro R, Konyukh M, Delorme R, Leblond C, Chaste P, Fauchereau F, et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 2010;26:363–72.View ArticlePubMedGoogle Scholar
- Frints SG, Marynen P, Hartmann D, Fryns JP, Steyaert J, Schachner M. CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. Hum Mol Genet. 2003;12:1463–74.View ArticlePubMedGoogle Scholar
- Wei MH, Karavanova I, Ivanov SV, Popescu NC, Keck CL, Pack S, et al. In silico-initiated cloning and molecular characterization of a novel human member of the L1 gene family of neural cell adhesion molecules. Hum Genet. 1998;103:355–64.View ArticlePubMedGoogle Scholar
- Tassano E, Biancheri R, Denegri L, Porta S, Novara F, Zuffardi O, et al. Heterozygous deletion of CHL1 gene: detailed array-CGH and clinical characterization of a new case and review of the literature. Eur J Med Genet. 2014;57:626–9.View ArticlePubMedGoogle Scholar
- Cuoco C, Ronchetto P, Gimelli S, Bena F, Divizia MT, Lerone M, et al. Microarray based analysis of an inherited terminal 3p26.3 deletion, containing only the CHL1 gene, from a normal father to his two affected children. Orphanet J Rare Dis. 2011;6:12.View ArticlePubMedPubMed CentralGoogle Scholar
- Pohjola P, de Leeuw N, Penttinen M, Kääriäinen H. Terminal 3p deletions in two families--correlation between molecular karyotype and phenotype. Am J Med Genet A. 2010;152A:441–6.View ArticlePubMedGoogle Scholar
- Hurley RS, Losh M, Parlier M, Reznick JS, Piven J. The broad autism phenotype questionnaire. J Autism Dev Disord. 2007;37:1679–90.View ArticlePubMedGoogle Scholar
- Jin H, Wu W, Zhang M. The preliminary analysis of SCL-90 in normal Chinese. Chinese J Nervous Metal Dis. 1986;05:260–3.Google Scholar
- Demyanenko GP, Siesser PF, Wright AG, Brennaman LH, Bartsch U, Schachner M, et al. L1 and CHL1 cooperate in thalamocortical axon targeting. Cereb Cortex. 2011;21:401–12.View ArticlePubMedGoogle Scholar
- Schmalbach B, Lepsveridze E, Djogo N, Papashvili G, Kuang F, Leshchyns’ka I, et al. Age-dependent loss of parvalbumin-expressing hippocampal interneurons in mice deficient in CHL1, a mental retardation and schizophrenia susceptibility gene. J Neurochem. 2015;135:830–44.View ArticlePubMedGoogle Scholar
- Malmgren H, Sahlén S, Wide K, Lundvall M, Blennow E. Distal 3p deletion syndrome: detailed molecular cytogenetic and clinical characterization of three small distal deletions and review. Am J Med Genet A. 2007;143A:2143–9.View ArticlePubMedGoogle Scholar
- Shuib S, McMullan D, Rattenberry E, Barber RM, Rahman F, Zatyka M, et al. Microarray based analysis of 3p25-p26 deletions (3p- syndrome). Am J Med Genet A. 2009;149A:2099–105.View ArticlePubMedGoogle Scholar
- Angeloni D, Lindor NM, Pack S, Latif F, Wei MH, Lerman MI. CALL gene is haploinsufficient in a 3p- syndrome patient. Am J Med Genet. 1999;86:482–5.View ArticlePubMedGoogle Scholar
- Girirajan S, Rosenfeld JA, Cooper GM, Antonacci F, Siswara P, Itsara A, et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet. 2010;42:203–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Liehr T. Cytogenetically visible copy number variations (CG-CNVs) in banding and molecular cytogenetics of human; about heteromorphisms and euchromatic variants. Mol Cytogenet. 2016;9:5.View ArticlePubMedPubMed CentralGoogle Scholar
- Girirajan S, Eichler EE. Phenotypic variability and genetic susceptibility to genomic disorders. Hum Mol Genet. 2010;19:R176–87.View ArticlePubMedPubMed CentralGoogle Scholar
- Conrad B, Antonarakis SE. Gene duplication: a drive for phenotypic diversity and cause of human disease. Annu Rev Genomics Hum Genet. 2007;8:17–35.View ArticlePubMedGoogle Scholar
- Te Weehi L, Maikoo R, Mc Cormack A, Mazzaschi R, Ashton F, Zhang L, et al. Microduplication of 3p26.3 implicated in cognitive development. Case Rep Genet. 2014;2014:295359.Google Scholar
- Salyakina D, Cukier HN, Lee JM, Sacharow S, Nations LD, Ma D, et al. Copy number variants in extended autism spectrum disorder families reveal candidates potentially involved in autism risk. PLoS One. 2011;6:e26049.View ArticlePubMedPubMed CentralGoogle Scholar
- Moghadasi S, Van Haeringen A, Langendonck L, Gijsbers ACJ, Ruivenkamp CAL. A terminal 3p26.3 deletion is not associated with dysmorphic features and intellectual disability in a four-generation family. Am J Med Genet. 2014;164:2863–8.View ArticleGoogle Scholar
- Yang CJ, Tan HP, Du YJ. The developmental disruptions of serotonin signaling may involved in autism during early brain development. Neuroscience. 2014;267:1–10.View ArticlePubMedGoogle Scholar
- Kleene R, Chaudhary H, Karl N, Katic J, Kotarska A, Guitart K, et al. Interaction between CHL1 and serotonin receptor 2c regulates signal transduction and behavior in mice. J Cell Sci. 2015;128:4642–52.View ArticlePubMedGoogle Scholar
- Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics. 2011;12:171–84.View ArticlePubMedGoogle Scholar
- Shoukier M, Fuchs S, Schwaibold E, Lingen M, Gärtner J, Brockmann K, et al. Microduplication of 3p26.3 in nonsyndromic intellectual disability indicates an important role of CHL1 for normal cognitive function. Neuropediatrics. 2013;44:268–71.View ArticlePubMedGoogle Scholar
- Palumbo O, Fischetto R, Palumbo P, Nicastro F, Papadia F, Zelante L, et al. De novo microduplication of CHL1 in a patient with non-syndromic developmental phenotypes. Mol Cytogenet. 2015;8:66.View ArticlePubMedPubMed CentralGoogle Scholar